# Lyophilization of Adeno-Associated Virus Serotypes for Storage and Global Distribution

## TL;DR

Researchers found that drying adeno-associated viruses in a sugar solution preserves their function, allowing storage at regular freezer temperatures and improving global access to gene therapy.

## Contribution

The study demonstrates that lyophilization in sucrose-based buffers preserves AAV transduction activity and enhances stability at higher temperatures.

## Key findings

- Lyophilization in sucrose preserved transduction activity for all nine tested AAV serotypes.
- AAV2, AAV2.5, and AAV6 showed increased transduction activity due to the sucrose excipient.
- AAV6 retained full activity for 8 weeks when stored at 4 °C or −20 °C.

## Abstract

Background: Adeno-associated viruses (AAVs) are widely used vectors for in vivo gene therapy, but their standard storage at −80 °C limits deployment in regions lacking ultracold infrastructure. Strategies enabling stable AAV storage at higher temperatures are needed to support global distribution. Methods: Nine AAV serotypes were lyophilized in simple sucrose-based buffers. Post-lyophilization vector integrity was assessed by measuring in vitro transduction efficiency using a luciferase reporter in cell-based assays. Stability of selected serotypes (AAV2.5 and AAV6) was further evaluated over 8 weeks under varying storage temperatures. Results: Lyophilization in sucrose preserved transduction activity for all tested serotypes (AAV1, AAV2, AAV2.5, AAV3, AAV4, AAV5, AAV6, AAV8, AAV9, and AAVrh10). Notably, AAV2, AAV2.5, and AAV6 exhibited 3- to 6-fold increases in transduction, an effect attributable to the sucrose excipient rather than the lyophilization process itself. Long-term stability of lyophilized vectors varied by serotype, temperature, and vial-seal integrity. AAV6 retained full activity for at least 8 weeks when stored at 4 °C or −20 °C. Conclusions: AAV vectors can be effectively lyophilized in simple sucrose solutions, enabling storage at standard −20 °C freezer temperatures while maintaining functional activity. Optimization of lyophilization buffers and excipients may further extend AAV stability at higher temperatures, improving feasibility for global gene therapy deployment.